Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc > ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

<< Previous

Bullboard Posts

Next >>

Comment by jimsenioron Apr 26, 2023 4:22pm

150 Views

Post# 35415507

RE:RE:RE:RE:ONCY to make an "Oral Presentation" on Bracelet-1 at ASCO

@westcoast1000. Yes, I agree with you. I am just thinking out loud and there are no guarantees of anything.
The patients are utmost in this equation. On the surface PDAC with tecentriq. mBC with avelumab.
The players seem to be Roche, Pfizer and Merck. The three of them form an entity and make an offer to ONCY. Shareholders have a say; we have an offer from 3 pharmas but they have become an entity.
Call it Pelacorp. Agreed, the above is not at all a likely scenario, but one can imagine. Cheers.

<< Previous

Bullboard Posts

Next >>

Sirios Resource discovers visible gold in Quebec